European regulators have recommended expanding use of the IL-23 inhibitor Skyrizi to treat moderate-to-severe plaque psoriasis in children aged 6 years or older who require systemic therapy.

The US FDA has approved guselkumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA) in children aged 6 years or older who weigh at least 40 kg, according ...

WESTLAKE VILLAGE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

A PDUFA target date of June 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for roflumilast cream 0.3% for ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

The initial choice of an oral nonbiologic systemic therapy for patients with psoriasis is often driven by insurance requirements; patients often must try and fail treatment with an older therapy ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in ...

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2, offering patients and caregivers an important alternative to ...